Service of Oncology, Hospital La Paz, Madrid, Spain.
Clin Transl Oncol. 2012 May;14(5):325-32. doi: 10.1007/s12094-012-0804-4.
After several decades of slow progress in the field of melanoma, significant advances have been reported in recent years. These include a better understanding of the molecular biology of the tumour, a new staging classification system, insights into the patterns of relapse in early stage, and new drugs for the treatment of advanced disease. Ipilimumab and vemurafenib have just been approved and provide a survival benefit in stage IV. Both compounds are under evaluation in the adjuvant setting, where interferon remains the only drug with proven efficacy. Further investigation is required to treat patients with primary or secondary resistance to new drugs.
在黑色素瘤领域经历了几十年的缓慢进展后，近年来取得了显著的进展。这些进展包括对肿瘤分子生物学的更深入理解、新的分期分类系统、对早期复发模式的深入了解以及治疗晚期疾病的新药。Ipilimumab 和 vemurafenib 刚刚获得批准，为 IV 期患者提供了生存获益。这两种化合物都在辅助治疗中进行评估，而干扰素仍然是唯一具有明确疗效的药物。需要进一步研究来治疗对新药原发性或继发性耐药的患者。
